- Resource Type:
LB9. Randomized, Multi-Center Phase 3 Trial of Pafolacianine during Intraoperative Molecular Imaging of Cancer in the Lung: Results of the ELUCIDATE Trial
May 17, 2022
Kazuhiro Yasufuku , Invited Discussant , Toronto General Hospital
Sunil Singhal , Abstract Presenter , Hospital of the University of Pennsylvania
102nd Annual Meeting, Boston, MA, USA
Hynes Convention Center, Room 311
Objective: To confirm the efficacy of Intraoperative Molecular Imaging (IMI) utilizing a targeted optical imaging agent (pafolacianine) to visually localize lung nodules, identify occult tumors and assess specimen tumor margins during a standard pulmonary resection.
Methods: Patients with suspected or biopsy-confirmed cancer in the lung scheduled for sublobar resection were administered a single intravenous infusion of pafolacianine (0.025 mg/kg), 1-24 hours prior to surgery. Intraoperatively, the patients underwent a white light evaluation, and, then, were randomly assigned to IMI or not (10:1). The primary study endpoint was the proportion of patients with a clinically significant event (CSE) which was defined as an unexpected event attributed to IMI with pafolacianine detecting cancer that would have been otherwise missed by standard surgical practice. Study CSEs were counted in three possibilities: IMI with pafolacianine (i) localized the index lung nodule that could not be located by white light, (ii) identified a synchronous malignant lesion, or (iii) identified a close surgical margin (<= 10mm).
Results: 112 patients were confirmed as eligible and administered pafolacianine. Of those receiving study drug, 111/112 proceeded to surgery and randomization; 1 patient withdrew consent prior to surgery. 100 patients were randomized to white light and IMI; 11 patients were assigned to white light only. Of the 100 patients randomized to IMI with pafolacianine, 54 patients (54%, 95% CI 43.7 – 64.0, p < 0.0001) had one or more CSEs. IMI with pafolacianine located the index lesion in 19 patients (19%, 95% CI 11.8 – 28.1) whose tumor could not be seen by white light. Also, IMI with pafolacianine identified occult synchronous malignant lesions in 9 patients (9%, 95% CI 4.2 – 16.4). Most (73%) IMI-identified synchronous malignant lesions were outside the planned field of resection. IMI with pafolacianine found 38 patients with close margins <=10 mm (38%, 95% CI 28.5 – 48.3). The investigators indicated a change in scope in the surgical procedure based on IMI with pafolacianine for 29% (22% increase, 7% decrease) of the patients. In the group randomized to IMI pafolacianine, there were 8/78 (10%) NSCLC patients whose stage was changed due to the CSE. No drug-related serious adverse events occurred. Pafolacianine infusion reactions, characterized primarily by mild gastrointestinal complaints, were seen in 19/112 (17%), of which 11 (10%) resulted in interruption of the infusion with eventual completion (6) or discontinuation (5).
Conclusions: Pafolacianine represents a first-in-class targeted imaging agent to aid the surgeon during surgery to visualize otherwise undetected cancers in the lung. In this trial, CSEs attributed to pafolacianine IMI occurred in more than 50% of patients undergoing surgery for pulmonary nodules. These findings suggest the use of IMI with pafolacianine may be a significant potential advancement to use during standard-of-care lung cancer surgery.
(Funded by On Target Laboratories, ClinicalTrials.gov number NCT04241315)
Sunil Singhal (1), Linda Martin (2), David Rice (3), Shanda Blackmon (4), Sudish Murthy (5), Sidhu Gangadharan (6), Rishindra Reddy (7), Inderpal Sarkaria (8), (1) Hospital of the University of Pennsylvania, Philadelphia, PA, (2) University of Virginia Health System, Charlottesville, VA, (3) N/A, Houston, TX, (4) Mayo Clinic, Rochester, MN, (5) Cleveland Clinic, Cleveland, OH, (6) Beth Israel Deaconess Medical Center, Boston, MA, (7) University of Michigan Medical Center, Ann Arbor, MI, (8) University of Pittsburgh Medical Center, Pittsburgh, PA
Dr. Kazuhiro Yasufuku is an internationally known Thoracic Surgeon with specific expertise in minimally invasive thoracic surgery and minimally invasive diagnostic procedures. He is the Head of the Division of Thoracic Surgery at the Toronto General Hospital, University Health Network. He is also Professor and Chair of the Division of Thoracic Surgery at University of Toronto. He holds the RFG Pearson – RJ Ginsberg Chair in Thoracic Surgery and William Coco Chair in Surgical Innovation for Lung Cancer. He serves as Director of Endoscopy and Director of the Interventional Thoracic Surgery Program at the University Health Network.
Dr. Yasufuku has been a leader in the field of minimally invasive diagnostics and therapeutics for thoracic malignancy. He co-developed the Convex Probe Endobronchial Ultrasound in collaboration with Olympus and has successfully introduced the clinical application of EBUS-TBNA in Thoracic Oncology. His clinical interests include minimally invasive diagnostic and surgery for thoracic oncology and lung transplantation. He leads the Thoracic Robotic Surgery Program and GTx Program at the University Health Network.
Sunil Singhal MD is the William Maul Measey Professor in the Department of Surgery at the University of Pennsylvania Perelman School of Medicine, Chief of the Division of Thoracic Surgery, and the Vice Chair for Translational Research for the Department of Surgery.